This HTML5 document contains 86 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/chemspider/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/chebi/
n18http://bio2rdf.org/drugbank:
n5http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/pharmgkb/
n30http://www.rxlist.com/cgi/generic/
n6http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/pubchem-substance/
n7http://linked.opendata.cz/resource/drugbank/property/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00724/identifier/drugbank/
n11http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00724
rdf:type
n3:Drug
n3:description
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
n3:dosage
n14:271B4EE9-363D-11E5-9242-09173F13E4C5 n14:271B4EEA-363D-11E5-9242-09173F13E4C5 n14:271B4EEB-363D-11E5-9242-09173F13E4C5 n14:271B4EEC-363D-11E5-9242-09173F13E4C5 n14:271B4EE7-363D-11E5-9242-09173F13E4C5 n14:271B4EE8-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# "Link":http://www.3m.com/us/healthcare/pharma/aldara/con_overview.jhtml # van Egmond S, Hoedemaker C, Sinclair R: Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol. 2007 Mar;46(3):318-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17343595 # Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb;3(2):196-200. Epub 2002 Jan 22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11812998 # Bilu D, Sauder DN: Imiquimod: modes of action. Br J Dermatol. 2003 Nov;149 Suppl 66:5-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14616337 # Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999 Jan;21(1):1-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10411278
n3:group
investigational approved
n3:halfLife
20 hours (topical dose), 2 hours (subcutaneous dose)
n3:indication
For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
n3:manufacturer
n15:271B4EE0-363D-11E5-9242-09173F13E4C5 n15:271B4EE1-363D-11E5-9242-09173F13E4C5 n15:271B4EDF-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00724 n18:DB00724
dcterms:title
Imiquimod
adms:identifier
n5:Imiquimod n21:36704 n22:51809 n23:46505394 n24:PA449972 n25:57469 n26:D02500 n27:0168-0432-24 n28:DB00724
n3:mechanismOfAction
Imiquimod's mechanism of action is via stimulation of innate and acquired immune responses, which ultimately leads to inflammatory cell infiltration within the field of drug application followed by apoptosis of diseased tissue. Imiquimod does not have direct antiviral activity. Studies of mice show that imiquimod may induce cytokines, including interferon-alpha (IFNA) as well as several IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. In the treatment of basal cell carcinoma, Imiquimod appears to act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. In treating basal cell carcinoma it may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion.
n3:packager
n15:271B4EDD-363D-11E5-9242-09173F13E4C5 n15:271B4EDE-363D-11E5-9242-09173F13E4C5 n15:271B4EDB-363D-11E5-9242-09173F13E4C5 n15:271B4EDC-363D-11E5-9242-09173F13E4C5
n3:patent
n6:7696159 n6:4689338
n3:synonym
Zartra R 837 Imiquimodum 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine Imiquimod
n3:toxicity
Symptoms of overdose include flu-like symptoms, such as fever, fatigue, headache, nausea, diarrhoea and muscle pain.
n8:hasAHFSCode
n9:84-92-00
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Imiquimod.htm
n12:hasConcept
n13:M0158430
foaf:page
n20:imiquimod.html n30:imiquimod.htm
n3:IUPAC-Name
n7:271B4EF1-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B4EF7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B4EF6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B4EF3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B4EF4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B4EF5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B4EEF-363D-11E5-9242-09173F13E4C5 n7:271B4F06-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B4EED-363D-11E5-9242-09173F13E4C5 n7:271B4EF0-363D-11E5-9242-09173F13E4C5 n7:271B4F08-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B4EEE-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n11:D06BB10
n3:H-Bond-Acceptor-Count
n7:271B4EFD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B4EFE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B4EF8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B4EF9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B4EFB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B4EFA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B4EFC-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed through skin (as a cream)
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
99011-02-6
n3:category
n3:containedIn
n10:271B4EE5-363D-11E5-9242-09173F13E4C5 n10:271B4EE6-363D-11E5-9242-09173F13E4C5 n10:271B4EE3-363D-11E5-9242-09173F13E4C5 n10:271B4EE4-363D-11E5-9242-09173F13E4C5 n10:271B4EE2-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B4F02-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B4F04-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B4F05-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B4F07-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B4F01-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B4F00-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B4F03-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B4EF2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B4EFF-363D-11E5-9242-09173F13E4C5